The estimated Net Worth of Hannah Valantine is at least $131 mil dollars as of 15 February 2024. Hannah Valantine owns over 2,915 units of BridgeBio Pharma Inc stock worth over $130,965 and over the last 3 years Hannah sold BBIO stock worth over $0.
Hannah has made over 6 trades of the BridgeBio Pharma Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Hannah exercised 2,915 units of BBIO stock worth $24,632 on 15 February 2024.
The largest trade Hannah's ever made was buying 3,433 units of BridgeBio Pharma Inc stock on 28 December 2021 worth over $44,492. On average, Hannah trades about 766 units every 35 days since 2021. As of 15 February 2024 Hannah still owns at least 4,679 units of BridgeBio Pharma Inc stock.
You can see the complete history of Hannah Valantine stock trades at the bottom of the page.
Hannah's mailing address filed with the SEC is C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO, CA, 94304.
Over the last 5 years, insiders at BridgeBio Pharma Inc have traded over $409,396,563 worth of BridgeBio Pharma Inc stock and bought 12,280,644 units worth $209,241,115 . The most active insiders traders include Global Investors Lp Viking ..., Andrew Lo y Genetic Disorder L.P.Kkr Ge.... On average, BridgeBio Pharma Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,173,197. The most recent stock trade was executed by Neil Kumar on 16 August 2024, trading 55,537 units of BBIO stock currently worth $1,554,481.
we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.
BridgeBio Pharma Inc executives and other stock owners filed with the SEC include: